New Delhi: Even as US President Donald Trump on Thursday announced a 100% tariff on imported branded and patented pharmaceutical drugs, requiring companies to have US-based manufacturing plants to avoid the duty, this will cause less damaged to India’s $25-billion export machine than markets fear. The reason, they say, lies in the very structure of India’s drug exports—dominated not by the branded and patented medicines targeted by Washington, but by the generics that form the backbone of the country’s pharma trade with America

“I’m putting a 100% import tax on pharmaceutical drugs unless the companies are building plants right here in the United States,” Trump said on Truth Social. “Breaking ground, under construction, that’s the deal. No exceptions,” Trump had wrote on his social media

See Full Page